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IL-25 (IL-17E) is a recently identifi  ed member 
of the IL-17 family of cytokines (1). It has been 
implicated in the initiation of type 2 immunity 
by driving the expression of IL-4, IL-5, and 
IL-13 (1, 2). In vitro, IL-25 is found in acti-
vated Th2 cells, bone marrow–derived mast 
cells, and alveolar macrophages (1, 3, 4). Re-
cently, we identifi  ed that IL-25 is produced by 
a population of CD4+ cells in mouse caecal 
patches (5). Expression of this cytokine is criti-
cal for immunity against helminth infections 
(5, 6). IL-25 protein administration or trans-
genic overexpression of IL-25 in mice resulted 
in Th2-like responses associated multiorgan in-
fl  ammation characterized by elevated ex pression 
of IL-4, IL-5, and IL-13, infl  ammatory cell infi  l-
tration, and epithelial cell hyper  plasia (1, 2, 7, 8). 
These fi  ndings suggest that IL-25 may be an im-
portant mediator of type 2   immune pathologies.
Besides IL-25, there are fi  ve  additional 
members that belong to the IL-17 family of 
cytokines. Although IL-25 promotes   allergic 
responses, IL-17A had been characterized to 
promote chronic infl  ammatory responses (9, 10). 
We have recently reported that IL-17A is pro-
duced by a population of IL-23–dependent 
pathogenic T cells required for the induction 
of autoimmune infl  ammation (11–13). This fi  nd-
ing has led to the proposal that these IL-17–
producing cells (called Th17) represent a novel 
subset of CD4+ Th cells (14–17). Several re-
cent reports have demonstrated that TGF-β 
and IL-6 are required for lineage commitment 
of IL-17–producing T cells (18–20), and this 
novel diff  erentiation pathway does not share 
transcription regulatory elements with Th1 and 
Th2 responses (21, 22). Indeed, we have iden-
tifi  ed an orphan nuclear receptor—retinoid-
  related orphan receptor γt (RORγt)—as the 
cri  tical transcription regulator that controls TGF-β– 
and IL-6–induced Th17 diff  erentiation (23). 
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Interleukin (IL)-25 is a member of the IL-17 family of cytokines. However, unlike the 
other members of this family, IL-25 promotes T helper (Th) 2 responses. We now show 
that IL-25 also regulates the development of autoimmune infl  ammation mediated by 
IL-17–producing T cells. We have generated IL-25–defi  cient (il25−/−) mice and found 
that they are highly susceptible to experimental autoimmune encephalomyelitis (EAE). 
The accelerated disease in the il25−/− mice is associated with an increase of IL-23 in the 
periphery and a subsequent increase in the number of infl  ammatory IL-17–, IFN𝗄-, and 
TNF-producing T cells that invade the central nervous system. Neutralization of IL-17 
but not IFN𝗄 in il25−/− mice prevented EAE, suggesting that IL-17 is a major disease-
promoting factor. IL-25 treatment at several time points during a relapse-remitting model 
or chronic model of EAE completely suppressed disease. IL-25 treatment induced elevated 
production of IL-13, which is required for suppression of Th17 responses by direct inhibi-
tion of IL-23, IL-1𝗃, and IL-6 expression in activated dendritic cells. Thus, IL-25 and 
IL-17, being members of the same cytokine family, play opposing roles in the pathogenesis 
of organ-specifi  c autoimmunity.
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These remarkable fi  ndings provide defi  nitive evidence that 
Th17 cells are indeed a bona fi  de T cell subset that is indepen-
dently regulated from Th1 and Th2.
Experimental autoimmune encephalomyelitis (EAE) is an 
autoimmune infl  ammatory disease of the central nervous sys-
tem (CNS) that serves as a disease model for human multiple 
sclerosis. EAE can be induced by passive transfer of myelin 
antigen–specifi  c Th17 or Th1, but not Th2 cells (13, 24, 25). 
In the infl  amed CNS, high levels of proinfl  ammatory cyto-
kines, such as IL-17, IL-18, IFNγ, TNF, and IP10 are ex-
pressed with very low levels of Th2 cytokines such as IL-4 
and -13 (26, 27). Studies have documented that redirecting 
the Th cell balance toward a type 2 response can suppress 
  autoimmunity (28–30). It is well accepted that type 2 responses 
provide multiple signals that inhibit IFNγ-producing Th1 
cells (31, 32). Recent in vitro studies have suggested that 
Th17 cells are also negatively regulated by IL-4 signaling 
pathways (21, 22). Nevertheless, very little is known about 
the in vivo regulation of Th17 cells. By generating IL-25–
  defi  cient mice, we investigated whether this potent Th2-
promoting cytokine plays a physiological role in regulating 
the development and function of Th1 and/or Th17 encepha-
litogenic T cells.
RESULTS
IL-25 is locally expressed in the CNS and protects from EAE
IL-25 is a potent cytokine that drives the production of type 
2 cytokines such as IL-4, IL-5, and IL-13 (1). During EAE 
priming, a broad range of cytokines is induced in C57BL/6 
mice, including the proinfl  ammatory cytokines IFNγ, IL-17, 
and IL-18, as well as the type 2 cytokines IL-4 and IL-13. To 
determine whether IL-25 plays a regulatory role during auto-
immune infl  ammation, we analyzed the expression of this 
cytokine during the course of EAE. We observed that IL-25 
mRNA is expressed in normal spinal cord as well as infl  amed 
CNS (Fig. 1 A). Analysis of CNS-resident cells indicated that 
IL-25 is predominantly expressed by microglia in the normal 
CNS (Fig. 1 B). Remarkably, microglia expressed ninefold 
more IL-25 mRNA during active EAE. In contrast, infl  am-
matory macrophages or infi  ltrating T cells do not express de-
tectible levels of IL-25 (unpublished data).
We generated IL-25–defi  cient mice (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061738/DC1) 
to determine whether this cytokine has a role in regulating 
clinical EAE. These mice have no developmental defects, and 
they generate litters of normal size. Males and females are 
born in equivalent numbers. Analysis of IL-25–defi  cient 
spleens showed normal numbers and percentages of B cells, 
T cells, and granulocytes. IL-25–defi  cient thymi had the same 
number of cells and the same percentages of CD4 and CD8 
double-negative, single-positive, and double-positive thy-
mocytes, when compared with C57BL/6 mice.
After myelin oligodendrocyte glycoprotein (MOG)   peptide/
CFA immunization, IL-25–defi  cient (il25−/−) mice showed 
accelerated EAE onset and enhanced disease severity com-
pared with WT C57BL/6 mice (Fig. 1 C). il25−/− mice 
  consistently developed EAE 2–3 d earlier than WT mice, and 
all died (100% mortality at day 17) when immunized at doses 
  optimized to give WT mice a nonlethal disease. In addition, 
incidence of disease reached 100% 6 d earlier in the il25−/− 
group (Fig. 1 C). Administration of IL-25 to MOG- immunized 
il25−/− completely protected the mice from EAE (Fig. S1 C), 
confi  rming that no other defects are responsible for the en-
hanced susceptibility of il25−/− mice to EAE. These results 
indicate that IL-25 may play an important role in suppressing 
the infl  ammatory responses that drive EAE pathogenesis.
IL-25 inhibits the Th17 response within the CNS
We have recently described an IL-23–dependent, IL-17– 
producing T cell population that is highly pathogenic in auto-
immune infl  ammatory diseases (13). Here, we found the 
Figure 1.  il25−/− mice are highly susceptible to EAE. (A) Taqman 
PCR analysis of IL-25 mRNA levels in spinal cords from C57BL/6 WT 
normal and diseased versus il25-LacZ-KI normal and diseased (n = 6 mice 
per group). Data shown are representative of at least two experiments. 
ND, not detectable. (B) IL-25 mRNA expression in CNS-resident microglia. 
Brain leukocytes were isolated from bone marrow chimeras expressing 
the CD45.2 allotype on radiation-resistant host cells and the CD45.1 
  allotype on donor leukocytes. CD11b+CD45.2loCD45.1neg resident microglia 
were purifi  ed from >100 irradiation bone marrow chimeric naive or dis-
eased (day 14) mice. Data from quantitative real-time PCR analysis for 
IL-25 expression were normalized to ubiquitin. (C) Clinical score (top) and 
percentage of incidence of disease (bottom) of C57BL/6 (WT) and il25−/− 
mice immunized with MOG/CFA s.c. on day 0 and PTX i.v. on days 0 and 2. 
The dagger indicates that by day 17, all il25−/− mice had died from EAE-
associated complications. Data shown are 7–9 mice per group and are 
representative of at least three experiments.JEM VOL. 204, January 22, 2007  163
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same Th17 cells as well as IFNγ-producing T cells in the 
CNS of il25−/− mice at an earlier time point and in greater 
numbers than in the WT mice (Fig. 2). 2 d before expected 
disease onset, the CNS of il25−/− mice contained fi  vefold 
more IL-17+ cells compared with the WT (Fig. 2 A). In 
contrast, the total numbers of IFNγ-producing T cells were 
similar in the il25−/− and WT control mice. Also, the total 
number of infl  ammatory macrophages was comparable between 
il25−/− and WT mice (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20061738/DC1). At the peak of 
disease, the il25−/− mice continue to have greater numbers 
of IL-17–producing T cells as well as IFNγ and TNF pro-
ducers (Fig. 2 B).
To examine whether the disease exacerbation observed in 
the il25−/− mice was mediated by Th17 and/or Th1 cells, we 
injected anti–IL-17 or anti-IFNγ antagonist mAbs into EAE-
primed mice. Blockade of IL-17 dramatically inhibited EAE, 
indicating that Th17 cells play a major role in EAE pathogen-
esis in il25−/− mice (Fig. 2 C). In contrast, anti-IFNγ treat-
ment had no eff  ect, consistent with studies demonstrating 
that Th1 cells only play a minor role in EAE (13). Thus, the 
absence of IL-25 leads to a more rapid and intense infi  ltration 
of pathogenic Th17 cells into the target organ, which drives 
an accelerated and exacerbated disease phenotype.
IL-25 is crucial for Th2 cytokine expression in the periphery
During EAE priming, myelin antigen–specifi   c T cells are 
generated in lymph nodes draining the sites of immunization. 
In these lymphoid organs, T cell diff  erentiation is depen-
dent on the cytokines produced by antigen-presenting cells. 
In draining lymph node (DLN) cells from il25−/− mice, we 
found a twofold higher expression of IL-23p19 mRNA than 
in WT controls at day 7 after immunization (Fig. 3 A). Inter-
estingly, the expression of IL-12p35 was not regulated by IL-25. 
To determine whether IL-25 aff  ected T cell priming and 
T cell subset diff  erentiation, we cultured DLN cells at day 7 
after immunization in the presence of MOG peptide to assess 
myelin antigen–specifi  c T cell responses. The Th2 cytokines 
IL-4, -5, and -13 were signifi  cantly reduced in DLN cul-
tures from il25−/− mice. IL- 17 and IFNγ levels were 
slightly higher in il25−/− DLN cultures; however, the dif-
ference did not reach statistical signifi  cance (Fig. 3 B). In 
addition to Th2 responses, regulatory T cells play a crucial 
role in limiting chronic infl  ammation. We found that il25−/− 
Figure 2.  Increased numbers of CNS-infi  ltrating infl  ammatory 
Th17 cells in il25−/− mice. (A) Intracellular cytokine staining of FITC-
gated CD4+ T cells isolated from the CNS of mice at day 7 after immuni-
zation (left, fl  ow cytometric analysis; right, calculated number of 
cytokine-producing cells). (B) Number of cytokine-producing CD4+ cells 
in CNS taken at peak of disease. For A and B, cells from four mice were 
pooled for intracellular cytokine analysis. Data are representative of 
two experiments. (C) Disease score of il25−/− mice immunized with MOG/
CFA (n = 4 mice per group) and treated with antibodies against IL-17 or 
IFNγ or with rat IgG1 control antibody. Data shown are representative of 
two experiments.
Figure 3.  Reduced Th2 cytokine production but normal regulatory 
T cell response in il25−/− DLN cells. (A) mRNA expression in MOG-
stimulated DLN cells taken at day 7 after immunization. Expression levels 
are normalized to ubiquitin. n = 5. Obtained DLN samples were pooled in 
three different pools for mRNA processing. (B) In vitro cytokine recall 
response. DLN cells from MOG-immunized il25−/− and WT mice were 
isolated at day 7 after immunization. Cells were stimulated with MOG 
peptide for 3 d and then restimulated with anti-CD3/anti-CD28 for 
2 additional days. Supernatants were from 24- or 72-h cultures as indi-
cated. Data are representative of three experiments. All cytokines were 
measured by cytometric bead array except for IL-13 and IL-17, which 
were detected by ELISA as described in Materials and methods. ND, not 
detectable. *, P < 0.05 (unpaired two-tailed t test). (C) Generation of reg-
ulatory T cells in il25−/− and WT mice before (pooled sample of two mice 
per group) and 7 d after (pooled sample of four mice per group) immuni-
zation with MOG/CFA. DLN cells were stained for CD4, CD25, and Foxp3.164  IL-25 (IL-17E) REGULATES TH17 RESPONSES | Kleinschek et al.
mice generated Foxp3+ regulatory T cells in numbers simi-
lar to WT controls during the course of EAE (Fig. 3 C). 
These data suggest that IL-25 plays a role in driving IL-4, 
IL-5, and IL-13 production but does not aff  ect regulatory 
T cell development.
Exogenous IL-25 inhibits EAE development and progression
We next determined whether exogenous IL-25 can suppress 
acute as well as relapse-remitting EAE. We used replication-
defi  cient adenoviral vectors (rAdVs) to induce local CNS or 
systemic IL-25 expression (33). SJL mice were used for these 
studies because they exhibit a multiple relapse-remitting pat-
tern of clinical disease. Using rAdV gene transfer vectors, we 
found that intracerebral delivery of IL-25–rAdV 1 d before 
immunization fully protected SJL mice from EAE (Fig. 4 A). 
Mice treated with GFP-control-rAdV were not protected. 
An intracerebral injection of 3 × 109 viral particles (Fig. 4 A) 
or i.v. injection of 1010 particles (not depicted) were equally 
eff  ective. Injection of IL-25–rAdV 10 d after initial priming 
could also block EAE (Fig. 4 A). The histological analysis of 
spinal cords 18 d after immunization shows large numbers of 
parenchymal and perivascular infi  ltrates in the control group. 
IL-25–rAdV–treated mice, in contrast, show minimal to no 
infi  ltrate (Fig. 4 B and Table S1, available at http://www.jem
.org/cgi/content/full/jem.20061738/DC1). We next exam-
ined whether IL-25 treatment can inhibit the eff  ector phase 
of CNS infl  ammation using a passive transfer model of 
EAE. Recombinant adenoviral vector–mediated IL-25 ex-
pression prevented EAE development when the treatment 
was given at the time of cell transfer, or even 3 d after cell 
transfer (Fig. 4 C).
In multiple sclerosis, patients usually suff  er from episodes 
of clinical disease relapse separated by periods of remission. 
Because IL-25–rAdV could protect from EAE when admin-
istered at either the priming stage (day 1 treatment) or during 
the eff  ector stage (day 10 treatment), we tested whether IL-25 
could be used therapeutically to modify clinical disease. 
  Remarkably, we found that IL-25–rAdV completely blocked 
EAE relapse when the treatment was given after the fi  rst epi-
sode of paralysis (Fig. 4 D). In contrast, control-rAdV–treated 
mice suff  ered two rounds of disease relapse over a period of 
51 d. Collectively, these results suggest that besides its ability 
to prevent disease, IL-25 may regulate eff  ector T cells and 
reduce their pathogenic functions.
IL-25 induced Th2 and suppressed Th17 responses
IL-25–defi  cient mice exhibited increased Th17 responses that 
promoted severe EAE pathology (Fig. 2). This result led us to 
examine the in vivo mechanisms of action of IL-25 treatment 
during disease induction. Daily s.c. injection with mouse IL 
(mIL)-25 protected the cytokine-treated mice from EAE 
(Fig. 5 A) as compared with saline-treated C57BL/6 mice as 
well as il25−/− mice. Given that the severe disease observed in 
il25−/− mice appeared to be driven by IL-17 rather than 
IFNγ (Fig. 2 C), we examined whether IL-25 could inhibit 
EAE in ifng−/− mice. Indeed, IL-25 treatment protected 
ifng−/− mice from EAE, suggesting that IL-25 regulation of 
the Th17 pathway is independent of IFNγ (Fig. 5 B).
To further characterize the immune responses regulated 
by IL-25, we profi  led the ex vivo gene expression pattern of 
DLN cells 7 d after MOG/CFA priming. We observed a 
marked down-regulation of IL-17 in IL-25–treated C57BL/6 
Figure 4.  IL-25 inhibits the effector phase of EAE and suppresses 
clinical disease relapse. (A) Clinical score of SJL mice (n = 5 per 
group) injected with 3 × 109 particles of indicated rAdV by intracerebral 
ventricular injection 1 d before or 10 d after immunization. (B) Histo-
pathological analysis of spinal cords from SJL mice at day 18 after 
immunization. Mice were treated with GFP-rAdV (left) or IL-25-rAdV 
(right) at day 1. (bottom) 10-fold magnifi  cation of boxed area in top panels. 
Bars, 100 μm. Results of histological analysis are summarized in Table S1 
(available at http://www.jem.org/cgi/content/full/jem.20061738/DC1). 
(C) Clinical score of mice (n = 4–5 per group) that received 2 × 107 acti-
vated PLP-specifi  c lymphocytes. Recipient mice were treated with 3 × 109 
particles of indicated rAdV at day 0 (top) or day 3 (bottom) after PLP-cell 
adoptive transfer. (left) Kinetics of mean disease score; (right) maximum 
disease score per individual mouse during 16 d of observation. (D) Clinical 
score of EAE-primed mice (n = 7–10 per group) injected with 3 × 109 
particles of indicated rAdV by an intracerebral ventricular route during 
disease remission (20 d after immunization, arrow). Mice were observed 
for two disease-relapse cycles. Results are representative of at least 
two experiments.JEM VOL. 204, January 22, 2007  165
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as well as ifng−/− mice (Fig. 5 C). Both genotypes showed an 
increased expression of IL-13 after IL-25 treatment. Interest-
ingly, IL-25 did not regulate the expression of total IFNγ 
mRNA levels in response to priming with MOG peptide and 
CFA. It is notable that most of the IFNγ response in the 
DLNs is directed against the mycobacterial component of the 
adjuvant (only 1–2% MOG-specifi  c T cell response and up 
to 10–30% anti-mycobacterial response). Thus, it is impor-
tant to determine the myelin-specifi  c T cell response. The 
in vitro MOG-specifi  c cytokine recall analysis showed that 
DLN cells from IL-25–treated mice produced less IL-17 and 
IFNγ as compared with saline-treated controls (Fig. 5 D). 
Type 2 cytokines such as IL-4, IL-5, and IL-13 were mark-
edly increased in IL-25–treated animals. Intracellular cyto-
kine staining of DLN cell cultures revealed lower relative 
and absolute numbers of IL-17–producing CD4+ T cells in 
IL-25–treated ifng−/− as well as C57BL/6 mice (Fig. 5 E). 
These fi  ndings established that treatment with recombinant 
IL-25 can suppress autoimmune infl  ammation by inducing 
Th2 while suppressing Th1 and Th17 responses.
IL-13 is required for IL-25–mediated protection from EAE 
and Th17 suppression
Previous studies as well as data shown here have demon-
strated that IL-25 strongly induced expression of IL-4 and 
-13, which are potent EAE inhibitors (27, 34). Therefore, we 
determined whether IL-25 suppression of EAE required the 
presence of these type 2 cytokines. Daily injection of mIL-25 
protein protected Il4−/− mice from EAE (Fig. 6 A). How-
ever, IL-25 could not provide protection to Il13−/− mice 
(Fig. 6 B). The requirement for IL-13 signaling was con-
fi  rmed by using il4ra−/− mice, which cannot respond to 
either IL-4 or IL-13. As shown in Fig. 6 C, IL-25 protein 
failed to protect the il4ra−/− mice as well. These fi  ndings 
show that IL-13 plays an important role in IL-25–mediated 
suppression of EAE.
Following the observation that IL-25 regulates EAE 
through suppression of Th17 responses, we used an in vitro 
cell culture system to further investigate the underlying 
mechanism. Naive DO11.10 CD4+ T cells were cocultured 
with LPS-activated CD11c+ DCs in the presence of neutral-
izing antibodies against IFNγ and IL-4. Addition of IL-23 to 
these cultures induced 10% of IL-17–producing T cells (Fig. 
6 D), whereas untreated cultures only contained 0.3% of IL-17 
producers (not depicted). The frequency of Th17 cells in-
duced by IL-23 was reduced by half when the cells were 
grown in the presence of IL-25, showing that IL-25 blocked 
the in vitro Th17 response, independent of IL-4 (Fig. 6 D). 
We also observed that IL-25 dramatically enhanced IL-13 
production, even in the presence of IL-23, anti–IL-4, and 
anti-IFNγ (Fig. 6 E).
We next determined the role of IL-13 in regulating Th17 
cells. We observed a reduction of the IL-23–induced IL-17 
production after addition of IL-25 (Fig. 6 F). This inhibitory 
eff  ect of IL-25 on IL-17 production was completely abol-
ished by the addition of neutralizing antibodies against IL-13 
Figure 5.  IL-25 induces Th2 and suppresses Th17 independent 
of IFN𝗄. (A) Clinical score of immunized WT and il25−/− mice compared 
with immunized WT mice injected daily s.c. with mIL-25 protein from day 1 
to the end of the experiment. Results are representative for at least four 
experiments with fi  ve to six mice per group. (B) Clinical score of ifng−/− 
(GKO) mice (n = 5 per group) injected daily with PBS or mIL-25 (s.c.) from 
days 1–12. Results are representative of two experiments. (C) DLN cells 
from MOG-immunized WT or ifng−/− mice treated with IL-25 or saline 
were analyzed for cytokine gene expression at day 7 after immunization 
(fi  ve mice per group; DLN cells were processed in three different pools for 
mRNA analysis). Cytokine gene expression was normalized to ubiquitin. 
(D) In vitro cytokine recall response. DLN cells from MOG-immunized WT 
mice treated with PBS or mIL-25 daily s.c. were isolated at day 7 after 
immunization. Cells were stimulated with MOG peptide for 3 d and restimu-
lated with anti-CD3/anti-CD28 for 2 additional days. Cytokine levels in 
supernatants were measured by CBA or ELISA. Cells from individual 
animals were cultured separately, and data are mean cytokine levels ± SD 
of three to fi  ve mice per treatment group. For IFNγ detection, nine mice 
per treatment group are shown. Data are representative of at least two 
experiments. *, P < 0.05. (E) DLN cells from MOG-immunized WT and 
ifng−/− (GKO) mice treated with IL-25 or saline (pool of four mice per 
group) were stimulated in vitro with MOG for 3 d followed by incubation 
with IL-2 for another 2 d. Frequencies (FACS plots) and absolute numbers 
(bar graph) of MOG-specifi  c IL-17–producing CD4+ cells were assessed. 
Data shown are representative of two experiments.166  IL-25 (IL-17E) REGULATES TH17 RESPONSES | Kleinschek et al.
(Fig. 6 F). Moreover, blockade of IL-13 led to enhanced 
IL-17 production. Addition of recombinant IL-13 to IL-23–
driven cultures reduced IL-17 production similar to the 
eff  ects of adding recombinant IL-25 (Fig. 6 F). We confi  rmed 
that IL-13 is a suppressor of IL-17 production using cells 
from MOG33-55 TCR transgenic mice (Fig. 6 G). Because 
the IL-13 receptor is not expressed on T cells (35), we exam-
ined the eff  ects of IL-13 on DC function. Remarkably, IL-13 
suppressed LPS-mediated IL-23, IL-1, and IL-6 expression, 
which are required for Th17 diff   erentiation and function 
(Fig. 6 H). Collectively, these data demonstrate that IL-25 
mediates EAE protection as well as Th17 suppression via 
IL-13. In turn, IL-13 directly suppresses DC production of 
Th17-promoting factors.
D  I  S  C  U  S  S  I  O  N 
In organ-specifi  c autoimmunity, the balance of cytokines is a 
key determinant of resistance or susceptibility. In EAE, dis-
ease susceptibility is thought to correlate with the expression 
of proinfl  ammatory cytokines such as IL-17, IFNγ, TNF, 
IL-6, and IL-1β. On the other hand, Th2 cytokines such as 
IL-4 and IL-13 have been shown to be important for pre-
venting or ameliorating disease (26, 27, 36). In the current 
study, we show that IL-25, a Th2-promoting cytokine, can 
protect mice from EAE, and loss of IL-25 results in enhanced 
proinfl  ammatory cytokine production and accelerated CNS 
pathology. This accelerated disease is also associated with an 
increased number of IL-17–, IFNγ- and TNF-producing 
T cells that invade the CNS. Even though IFNγ-producing 
cells can induce EAE and their presence within the CNS 
likely contributed to acute infl  ammation, neutralization of 
IFNγ in il25−/− mice did not lead to disease amelioration. In 
contrast, anti–IL-17 mAb treatment signifi  cantly  inhibited 
EAE in il25−/− mice, suggesting that the IL-17 immune 
pathway plays an important role in the disease process. We 
also demonstrate that IL-25 treatment protects mice from 
EAE, and this protection clearly depends on the suppres-
sion of IL-17–producing T cells. Thus, the presence of 
IL-25 supports a cytokine environment that limits chronic 
infl  ammatory responses.
IL-25 is constitutively expressed in the CNS (37). Inter-
estingly, EAE-resistant BALB/c mice constitutively expressed 
higher CNS levels of IL-25 mRNA compared with moder-
ately susceptible C57BL/6 (unpublished data). In addition, 
we found that resident microglia is a primary cellular source 
of IL-25 in a normal CNS. Importantly, there is a ninefold 
induction of IL-25 expression in microglia during CNS 
infl  ammation. This IL-25 expression pattern supports the 
  hypothesis that microglia have protective roles during chronic 
CNS infl  ammation. The observation of tissue-specifi  c ex-
pression of IL-25 is consistent with our recent study in a 
  helminth infection model, where we showed that locally 
expressed IL-25 is crucial for the ability of mice to clear the 
gut parasite Trichuris muris (5). Moreover, IL-25 is also con-
stitutively expressed in the lungs (1). Again, highly special-
ized tissue-resident cells, in this case, alveolar macrophages, 
were shown to be the source of IL-25 (4). Thus, IL-25 is ex-
pressed in organ systems where regulation of infl  ammation is 
of critical importance. In healthy digestive and respiratory 
tracts, an anti-infl  ammatory environment has to be maintained 
because of the constant exposure to commensal microbes. 
In immune-privileged sites, such as the eyes or the CNS, 
  infl  ammation must be constrained because of the detrimental 
consequences of tissue swelling responses in these organs.
Figure 6.  IL-13 is required for Th17 suppression in IL-25–
  mediated protection from EAE. Clinical score of il4−/− (A), il13−/− 
(B), or il4ra−/− mice (C), with fi  ve mice per group injected daily with PBS 
or mIL-25 (s.c.) from days 1–12. Results are representative of two experi-
ments. (D–F) Naive T cells and LPS-activated CD11c+ DCs were obtained 
from DO11.10 × RAG−/− mice (pool of fi  ve mice) and incubated for 3 d 
with IL-23 in the presence of OVA peptide. IFNγ and IL-4 were neutralized 
in these cultures. (D) The effect of IL-25 addition on the number of IL-23–
induced IL-17 producers was assessed by intracellular staining for IL-17. 
(E) IL-13 expression in these cultures was determined by LUMINEX. (F) The 
modulation of IL-17 protein production in IL-23–driven cultures by IL-25, 
IL-25 plus anti–IL-13, and IL-13 is shown in percentage of IL-23–induced 
IL-17 production without addition of exogenous factors (mean IL-17 pro-
duction is 202.3 pg/ml, assessed by LUMINEX). Data shown are repre-
sentative of at least two experiments (D and E) or pooled data from two 
similar experiments (F). (G) Purifi  ed MOG33-55 TCR transgenic T cells and 
LPS-activated CD11c+ DCs were incubated for 4 d with IL-23 in the pres-
ence of MOG peptide and neutralizing antibodies against IFNγ and IL-4. 
IL-17 production after incubation with IL-25, IL-25 plus anti–IL-13, and 
IL-13 was measured by LUMINEX. (H) DCs were purifi  ed from spleens and 
superfi  cial lymph nodes and activated with LPS with or without addition 
of IL-13. After 24 h, mRNA expression relative to ubiquitin was measured 
for IL-23p19, IL-1β, and IL-6 by quantitative real-time PCR. Shown is an 
experiment using DCs from C57BL/6 mice representative of two C57BL/6 
and two BALB/c experiments with a similar outcome (n = 3–5 mice 
pooled per experiment).JEM VOL. 204, January 22, 2007  167
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During EAE priming, IL-25 induces IL-4, IL-5, and IL-13 
in the periphery. Although IL-4 and IL-13 have been re-
ported to be protective in EAE, there is little evidence that 
IL-5 plays a regulatory role in EAE (38). In contrast, the role 
of IL-4 in suppressing organ-specifi  c autoimmunity is well 
documented (29, 33, 39–41). IL-4 is required for the diff  er-
entiation of Th cells toward the Th2 pathway (42, 43). In 
EAE, deviation of the immune system toward a Th2 response 
correlates with disease resistance (44, 45), and delivery of IL-4 
in vivo can modulate the immune response to ameliorate 
  disease (29, 46). Surprisingly, IL-25 treatment still protected 
il4−/− mice from EAE, suggesting that the levels of IL-4 in-
duced by IL-25 treatment are not suffi   cient for EAE suppres-
sion. In contrast to IL-4, we found that IL-13 is necessary for 
IL-25–mediated EAE suppression. Both IL-4Rα– (required 
for IL-13 signaling) and IL-13–defi  cient mice were not pro-
tected by IL-25 treatment, suggesting that IL-25 is acting via 
IL-13 to suppress disease. On its own, IL-13 protects rats 
from EAE, through its ability to deactivate infl  ammatory 
macrophages, as well as suppressing the production of nitric 
oxide, IL-1β, and TNF (27).
Here, we demonstrate a novel role for IL-13 in inhibiting 
Th17 diff  erentiation and function. However, IL-13 can only 
partially inhibit IL-17 production. In contrast, IL-4 can com-
pletely block IL-17 response, consistent with two recent re-
ports (21, 22). These results suggest that IL-13 and IL-4 
may use diff  erent mechanisms to inhibit Th17 cells. Indeed, 
although T cells are shown to express the shared IL-4/IL-13 
receptor chain IL-4Rα, the specifi  c IL-13 receptor is not 
  expressed on T cells (35). Therefore, IL-13 might act by 
  inhibiting DC function (27). Indeed, we observed that 
IL-13 blocked Th17-promoting factors such as IL-1β, IL-6, 
and IL-23.
It is intriguing that in our Th17 cultures (DC-derived IL-6, 
IL-1β, TGF-β plus exogenous IL-23, anti–IL-4, and anti-
IFNγ), IL-25 still induced IL-13 production. We have 
observed that IL-25 led to IL-13 production in CD4+ T cell 
populations in vitro (unpublished data). However, it is still 
unclear which T cell populations are responsive to IL-25 
in vivo. It is also possible that IL-25 acts on NKT cells, which 
play an important role in the early IL-4 production during an 
immune response (47, 48). NKT cells secrete IL-4, IL-13, 
and IFNγ upon activation and have an important immuno-
regulatory role (49, 50). Interestingly, activation of NKT 
cells by the synthetic ligand α-galactosylceramide can induce 
IL-4 and IL-13, which protects mice from autoimmune 
  infl  ammation (51–53). Another possible target of IL-25 may be 
antigen-presenting cells such as DCs. The IL-25 receptor, 
IL-17RB, has been found to be up-regulated in DCs under 
Th2-inducing conditions (54). Consistent with pervious re-
ports (55, 56), we observed that IL-25 could induce IL-13 
mRNA expression in cultured DCs (unpublished data). Fur-
ther studies are needed to understand how these IL-13–
  expressing cells regulate Th17 development.
We have shown that although IL-25 and IL-17 are mem-
bers of the same cytokine family, they play opposing roles in 
the regulation of organ-specifi  c autoimmunity. The type 2 
responses promoted by IL-25 drive a novel regulatory mech-
anism for controlling Th17 responses. Unexpectedly, this 
regulation relies on IL-13 rather than IL-4, suggesting that 
IL-13 may be secreted at higher levels in the target organs 
during autoimmune infl  ammation. This protective mecha-
nism is important because the lack of IL-25 causes devastating 
infl  ammatory responses during EAE. Thus, IL-25 expression by 
CNS-resident microglia may provide an important mechanism 
that limits brain and spinal cord infl  ammation. This unique 
property suggests that IL-25 may be a potential therapeutic 
agent for a range of organ-specifi  c infl  ammatory disorders.
MATERIALS AND METHODS
Animals. il25−/− mice were generated in the C57BL/6 background (Fig. 
S1). A C57BL/6J genomic BAC library (Genome Systems) was screened 
with a full-length mIL-25 cDNA probe, and a positive clone was identifi  ed 
and used to generate a shotgun plasmid library (SeqWright). Subclones were 
sequenced and assembled to generate 15,747 bp of sequence encompassing 
the il25 locus. Using a genomic subclone (F6), a BglII site was introduced in 
exon1 at the ATG via site-directed mutagenesis. This clone was digested with 
BglII, and a 5,442-bp 5′ region of homology was cloned into the unique 
BglII site of pbgal-basic (CLONTECH Laboratories, Inc.). A 1,049-bp 3′ 
region of homology was generated by PCR using a genomic subclone (C6) 
incorporating unique SpeI and NotI restriction sites and cloned into pBS-
lox-Neo-lox. This plasmid was digested with SalI, and the lox-Neo-lox-3′ 
region of homology was ligated into the unique SalI site of the 5′ arm-
pbgal-Basic, yielding the fi  nal targeting vector. The NheI-linearized targeting 
vector was electroporated into C57BL/6 ES cells, and Neo-resistant clones 
were analyzed for homologous recombination (HR) using a PCR-based 
screening strategy followed by Southern blot confi  rmation with 5′ and 3′ 
probes. A confi  rmed HR clone was electroporated with a Cre recombinase 
expression–containing plasmid, and several Neo-sensitive clones were screened 
using Southern blot to identify the Neo-fl  ipped HR il25-LacZ ES line. This 
line was injected into C57BL/6 blastocysts, and il25-LacZ-KI−/− progeny 
were obtained by intercrossing il25-LacZ-KI+/− animals. A PCR-based geno-
typing strategy was developed to track the il25 WT and knockin alleles. il25-
targeted allele, sense, 5′-G  C  T  G  A  C  T  C  T  C  A  A  C  A  T  T  C  T  A  C  T  C  C  T  C  C  -3′, 
and antisense, 5′-C  C  T  G  C  T  G  C  T  T  C  A  G  G  T  A  G  G  G  C  T  T  T  G  -3′; WT il25 
  allele, sense, 5′-C  T A  C  A  G  A  C  A  G  G  C  T  C  C  C  A  C  A T  G  G  A  C  C  -3′, and antisense, 
5′-C  C  T  G  C  T  G  C  T  T  C  A  G  G  T  A  G  G  G  C  T  T  T  G  -3′.
C57BL/6J and il4−/− (C57BL/6-Il4tm1Nnt/J) mice were obtained from 
The Jackson Laboratory. il13−/−, ifng−/−, and DO11.10 × Rag−/− mice 
were from the DNAX colonies. Breeding pairs of il4ra−/− mice were ob-
tained from F. Brombacher (University of Cape Town, Rondebosch, South 
Africa) and a colony maintained at DNAX. C57BL/6 MOG33-55 TCR trans-
genic mice were obtained from T. Backstrom (Malaghan Institute of Medi-
cal Research, Wellington, New Zealand). Animals were maintained in a 
specifi  c pathogen–free environment and tested negative for pathogens in 
routine screening. All experiments were performed following the guidelines 
of the DNAX Institutional Animal Care and Use Committee.
EAE induction. For studies in gene-defi  cient mice, we used the C57BL/
6-MOG33-55 model of EAE, as il25−/−, ifng−/−, il4−/−, il4ra−/−, and il13−/− 
were bred on a C57BL/6 background. C57BL/6 mice were immunized 
with 100 μg MOG33-55 peptide and CFA containing 1 mg H37Ra s.c. on 
day 0 and 100 ng pertussis toxin (PTX) i.v. on day 0 and again on day 2. For 
disease-prevention studies in relapse-remitting EAE, SJL mice were immu-
nized with 50 μg PLP139-151 plus CFA containing 200 μg H37Ra s.c. on day 0. 
SJL mice were given 100 ng PTX on day 0 only. For passive transfer EAE, 
donor SJL mice were immunized with 50 μg PLP139-151 in CFA (no PTX 
adjuvant was used for the donor mice). 7–8 d after PLP priming, DLN cells 
were stimulated for 3–4 d with 20 μg/ml PLP139-151, and 2 × 107 viable cells 168  IL-25 (IL-17E) REGULATES TH17 RESPONSES | Kleinschek et al.
were transferred into naive recipient SJL mice. Clinical scores were as fol-
lows: tail weakness, grade 1; hind limb weakness, grade 2; partial hind limb 
paralysis and weight loss, grade 3; paraplegia and incontinence, grade 4; 
quadriplegia and wasting, grade 5; and moribund, grade 6.
IL-25, IL-25–rAdV, and antibody treatment. Recombinant mouse IL-25 
protein was administered daily s.c., beginning at 1 d before MOG immuni-
zation. For administration into the CNS, rAdV gene transfer vectors were 
suspended in 10 μl PBS and injected into the right-lateral cerebral ventricle 
using a 28-gauge needle, as described previously (33). For peripheral deliv-
ery, rAdVs suspended in 100 μl PBS were injected into the tail vein. Anti-
bodies for neutralization of IFNγ (clone XMG1.2, rIgG1; 200 μg per 
mouse) and IL-17 (clone 1D10, rIgG1; 1 mg per mouse) and the corres-
ponding isotype control (rat IgG1; 1 mg per mouse) were administered s.c. 
once a week starting 1 d before immunization.
Isolation of CNS infl  ammatory cells. C57BL/6 mice were immunized 
as described. At day 7 (before disease onset) and at peak disease (day 11 in the 
il25−/− and day 14 in WT), mice were killed, and CNS-infi  ltrating T cells, 
macrophages, and resident microglia were isolated by digesting brain and 
spinal cord homogenate with collagenase and DNase followed by Percoll 
gradient centrifugation as described previously (57). We determined the 
number of CD4+CD45hi T cells and CD4−CD11b+CD45hi infl  ammatory 
macrophages in the CNS by multiplying the percentage of lineage marker–
positive cells by the total number of mononuclear cells isolated from the 
CNS. For further characterization, intracellular cytokine staining was per-
formed (see the following section). For analysis of IL-25 mRNA expression 
in the CNS, infl  ammatory macrophages and resident microglia were isolated 
from irradiation bone marrow chimeric mice produced by the injection 
of CD45.1 B6 bone marrow cells into irradiated CD45.2 C57BL/6 
mice. The CD11b+CD45.1hiCD45.2neg infl  ammatory macrophages and 
CD11b+CD45.2loCD45.1neg resident microglia (radiation-resistant cells 
  remaining with the host CD45 allotype) were purifi  ed by three-color fl  ow 
cyto  metric sorting from >100 irradiation bone marrow chimeric mice (11). 
Purifi  ed and sorted cells from naive or diseased animals were pooled 
(microglia or infl  ammatory macrophages) and analyzed by quantitative real-
time PCR for IL-25.
Intracellular staining. CNS-infi  ltrating cells were obtained from MOG/
CFA-immunized mice as described in the previous paragraph. Cells were 
stained with anti–CD4-FITC, fi  xed, and permeabilized with Cytofi  x/Cyto-
perm (BD Biosciences). Intracellular staining with antibodies against IL-17, 
IFNγ, and TNF (BD Biosciences) was performed and analyzed by fl  ow 
  cytometry. T cells were identifi  ed by gating on CD4. The number of   cytokine-
producing cells was calculated from the percentage of cytokine-positive 
CD4+ T cells. We determined the number of CD4+ T cells in the CNS by 
multiplying the percentage of lineage marker–positive cells by the total 
number of mononuclear cells isolated from the CNS. For intracellular cyto-
kine staining of DLN cells, DLNs were taken at day 7 after immunization. 
After 3 d of culture with MOG, cells were incubated with IL-2 for 2 d. Cells 
were then incubated with PMA/ionomycin in the presence of Golgi-Plug 
(BD Biosciences) for 5 h, and intracellular staining was performed as de-
scribed. Absolute cell numbers were obtained by multiplying relative num-
bers with total number in culture plate well. For intracellular Foxp3-staining, 
DLNs were taken at day 7 after immunization and processed immediately for 
CD4, CD25, and Foxp3 staining with the Mouse regulatory T cell staining 
kit (eBioscience).
Cytokine assays. Mice were immunized as described. DLNs (axillary, bra-
chial, and inguinal) were isolated at day 7, before disease onset. Single-cell 
suspensions were plated at 6 × 106 cells/well in 24-well plates in the pres-
ence of 100 μg/ml MOG33-55 peptide in cRPMI. Supernatants were 
  collected after 3 d of culture. Cells were rested for 4 d in the presence of 
1–2 ng/ml IL-2. After 7 d, cells were restimulated with 10 μg/ml αCD3 
(plate bound) plus 5 μg/ml αCD28, and supernatants were collected at 
24 and 72 h. Alternatively, supernatants were collected at 48 h after restimu-
lation. Cytokine production was analyzed by sandwich ELISA (IL-13 and 
IL-17 kits; R&D Systems) or cytometric bead array (Mouse Th1/Th2 cyto-
kine CBA and Infl  ammation CBA kits; BD Biosciences). For the CBA assay, 
50 μl of supernatant was incubated with a mixture of beads coated with cap-
ture antibodies for IL-2, IL-4, IL-5, IFNγ, or TNF (for Th1/Th2 kit), or 
IL-6, IL-10, MCP-1, IFNγ, TNF, or IL-12p70 (for Infl  ammation kit). 
Addition of the PE-conjugated detection antibodies forms a sandwich complex. 
After 2 h of incubation and one wash, samples were analyzed by fl  ow cyto-
metry. Standard curves were generated from analysis of titrated cytokine stan-
dards (at least 10 serial dilutions) using the BD CBA analysis software, which 
runs on Excel (Microsoft). IL-13 and IL-17 in samples from in vitro Th17 
assays were assessed using a multiplexing bead array (Linco) according to the 
manufacturer’s recommendations. In brief, 25 μl of supernatants were incu-
bated with assay buff  er, and fl  uorescent beads were conjugated to capture 
antibodies for the cytokines of interest. After addition of the detection anti-
body mix and PE-conjugated streptavidin, plates were read on a LUMINEX 
100 machine (Luminex). Data were analyzed using Masterplex QT 
(MiraiBio) and GraphPad Prism (GraphPad).
Histological analysis. Spinal cords were taken at day 18 after immuniza-
tion. Fixated tissue was embedded in paraffi   n wax, and 5-μm-thick longitu-
dinal sections were stained with hematoxylin and eosin. Lesions were 
counted, and each scored based was on the size of the infl  ammatory infi  ltrate 
(score 1, <10 cells; score 3, 10–50 cells; score 5, >50 cells). The total num-
ber of lesions was assessed per section, and mean and SD were calculated per 
treatment group. Cumulative score per section was divided by total number 
of lesions to obtain a mean lesion score per section. Mean and SD were cal-
culated per treatment group.
Quantitative real-time PCR. DLN were taken at day 7 after immunization 
from fi  ve mice per indicated group and processed in three diff  erent pools. Single-
cell suspensions were prepared by mashing lymph nodes through a 70-μm cell 
strainer (BD Biosciences). CNS leukocytes were prepared and purifi  ed as 
described. DC cultures were prepared as stated in the following section. Total 
RNA was prepared from frozen cell pellets using RNeasy columns (QIAGEN), 
and 5 μg were subjected to treatment with DNase (Ambion) and reverse tran-
scribed using Superscript II (Invitrogen) with oligo (dT)15 primers (Roche) and 
random hexamers (Promega). Cytokine-specifi  c mRNA was measured by real-
time quantitative PCR (Applied Biosystems). Gene expression levels were nor-
malized to ubiquitin.
In vitro cultures. Spleens and lymph nodes were taken from naive 
DO11.10 × RAG−/− BALB/c mice, which only produce OVA peptide–
specifi  c naive T cells. Cells were also isolated from naive C57BL/6 MOG33-55 
TCR Tg (clone 2D2) mice or from WT C57BL/6 mice (for DC isolations). 
CD4+ as well as CD11c+ cells were purifi  ed by magnetic bead separation 
(MACS; Miltenyi Biotec) after collagenase digestion of tissue. For Th17 
  polarization, CD11c+ cells (5 × 105 cells per well in a 24-well plate) were 
activated with 0.5 ng/ml LPS and incubated with OVA peptide as well as 
neutralizing antibodies against IL-4 (BVD4-1D11; 10 μg/ml) and IFNγ 
(XMG1.2; 10 μg/ml) for 2 h before addition of CD4+ cells in a 1:1 ratio. 
20 ng/ml IL-23 was added to expand Th17 cells. Depending on the experi-
mental setup, 100 ng/ml IL-25, 100 ng/ml IL-3, or 10 μg/ml anti–IL-13 
were added to the cultures. Cultures with no cytokine addition served as a 
control. After 72 h, cells were incubated with 5 ng/ml IL-2 for an additional 
48 h. Supernatants were then sampled for cytokine analysis, and cells were 
stimulated with PMA/ionomycin for 5 h in the presence of Golgi-Plug (BD 
Biosciences). Intracellular staining for IL-17 was performed as described. For 
DC cultures, 106 CD11c+ DCs were plated in a 48-well plate, rested over-
night, and incubated with or without IL-13 1 h before addition of LPS. Cells 
were harvested after 24 h and prepared for gene expression analysis.
Online supplemental material. Fig. S1 contains a schematic representation 
of the WT il25 locus, the arms used for generating the targeted allele, and the JEM VOL. 204, January 22, 2007  169
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Neo-fl  ipped-LacZ knockin allele. Fig. S2 shows similar numbers of CNS-
  infi  ltrating infl  ammatory macrophages and total T cells in WT versus il25−/− 
mice at several time points after MOG-EAE induction. Table S1 summarizes 
the results of the analysis of spinal cord sections from IL-25–treated versus un-
treated EAE mice (experiment shown in Fig. 4 B) and confi  rms the enhanced 
resistance of IL-25–treated mice. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20061738/DC1.
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